243 related articles for article (PubMed ID: 7873373)
21. [Neurologic manifestations of monoclonal gammapathies].
Uldry PA; Steck AJ; Regli F
Schweiz Med Wochenschr; 1984 Nov; 114(47):1678-85. PubMed ID: 6096963
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
24. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
25. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
26. Myeloma and macroglobulinemia: what are the criteria for diagnosis?
Stone MJ
Clin Lymphoma; 2002 Jun; 3(1):23-5. PubMed ID: 12141951
[TBL] [Abstract][Full Text] [Related]
27. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
28. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance.
Diamond T; Levy S; Smith A; Day P; Manoharan A
Intern Med J; 2001 Jul; 31(5):272-8. PubMed ID: 11512598
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
Ouzzif Z; Doghmi K; Messaoudi N; Bouhsain S; El Machtani S; Biaz A; Rachid A; Dami A; Bezza A; El Maataoui A
Cancer Rep (Hoboken); 2023 May; 6(5):e1814. PubMed ID: 36999311
[TBL] [Abstract][Full Text] [Related]
30. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
31. T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia.
San Miguel JF; Caballero MD; Gonzalez M
Am J Hematol; 1985 Nov; 20(3):267-73. PubMed ID: 3933332
[TBL] [Abstract][Full Text] [Related]
32. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
34. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.
Klein CJ; Moon JS; Mauermann ML; Zeldenrust SR; Wu Y; Dispenzieri A; Dyck PJ
Can J Neurol Sci; 2011 Mar; 38(2):289-95. PubMed ID: 21320835
[TBL] [Abstract][Full Text] [Related]
35. Paraproteins: a regional South Australian experience.
Roberts-Thomson PJ; Nikoloutsopoulos T; Smith AJ
Asian Pac J Allergy Immunol; 2002 Sep; 20(3):187-95. PubMed ID: 12587843
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal gammopathy of undetermined significance (MGUS).
Kyle RA
Baillieres Clin Haematol; 1995 Dec; 8(4):761-81. PubMed ID: 8845571
[TBL] [Abstract][Full Text] [Related]
37. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study.
Pérez-Escurza O; Flores-Montero J; Óskarsson JÞ; Sanoja-Flores L; Del Pozo J; Lecrevisse Q; Martín S; Reed ER; Hákonardóttir GK; Harding S; Þorsteinsdóttir S; Rögnvaldsson S; Love TJ; Durie B; Kristinsson SY; Orfao A
Blood Cancer J; 2023 Dec; 13(1):182. PubMed ID: 38072838
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological correlates of IgM paraproteinemias.
Owen RG; Parapia LA; Higginson J; Misbah SA; Child JA; Morgan GJ; Jack AS
Clin Lymphoma; 2000 Jun; 1(1):39-43; discussion 44-5. PubMed ID: 11707811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
